AZNAstraZenecaInvite-only sign-up
Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Durvalumab
Cancer
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 214 (planned)
- Started
- Apr 19, 2022
- Main results expected
- Dec 31, 2026
- Fully finished
- Dec 31, 2027
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Number of participants with serious adverse events as assessed by Common Terminology Criteria for Adverse Events (CTCAE) v5.0
Measured over: From baseline up to follow up at 90 days after the last dose of study drug.
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT05303532 · record last updated 2026-10-26 · checked 2026-11-09 15:47 UTC